Constitutive Somatostatin Receptor Activity Determines Tonic Pituitary Cell Response

Journal of Clinical Endocrinology & Metabolism (Impact Factor: 6.21). 03/2009; 94(2):703. DOI: 10.1210/me.2008-0361
Source: PubMed


Somatostatin (SRIF) binds G protein-coupled SRIF receptor subtypes (SST1, -2, -3, -4, and -5) to regulate cell secretion and proliferation. Hypothalamic SRIF inhibits pituitary growth hormone, thyroid stimulating hormone, and ACTH secretion. We tested SRIF-independent constitutive SST activity in AtT20 mouse pituitary corticotroph cells in which ACTH secretion is highly sensitive to SRIF action. Stable transfectants expressing SST2 or SST5 were sensitized to selective agonist action, and constitutive SST receptor activity was demonstrated by forskolin and pertussis toxin cAMP cell responses. Persistent constitutive SST activity decreased cell ACTH responses to CRH through decreased expression of CRH receptor subtype 1. Decreased dopamine receptor type 1 expression was associated with attenuated dopamine agonist action, whereas responses to isoproterenol were enhanced through increased beta 2-adrenoreceptor expression. Thus, integrated pituitary cell ACTH regulation is determined both by phasic SRIF action, as well as by tonic constitutive SST activity, independently of SRIF. (Molecular Endocrinology 23: 337-348, 2009)

Download full-text


Available from: Cuiqi Zhou, Jun 19, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Contemporary (event to decadal-scale) morphological changes in two large braided rivers in Canterbury, New Zealand, are described, along with laboratory studies that support the field observations. In the process, some new developments in field and laboratory methods for investigating morphological change in braided rivers are presented, and Paola's (2001) hypothesis that braiding tendency should be influenced by a river's ability to turn over its bed within the characteristic time for riparian vegetation to establish and grow to a mature, scour-resistant state is examined. The lower Waitaki River has been regulated for hydropower since 1935, and since then vegetation has encroached over the riverbed and braiding intensity for a given discharge has reduced. Measurements of vegetation removal by floods indicate that floods are not able to turn over the bed fast enough to contain vegetation encroachment, and the present braiding state is held by virtue of a regular spraying programme. In contrast, on the unregulated and sparsely vegetated Waimakariri River, remotely sensed high-resolution topographic surveys using LiDAR and digital photogrammetry have shown that even sub-annual floods turn over large proportions of the braidplain. The laboratory studies show that a braided river will evolve into a single-thread channel when its bed is invaded by vegetation and floods are too infrequent to contain the vegetation growth. Collectively, the field and laboratory evidence confirms that Paola's (2001) dimensionless time-scale parameter is a reasonable first-order predictor of whether floods or vegetation will achieve ascendancy, driving a river towards either braided or single-thread end-points, respectively.
    No preview · Article · Jan 2007 · Developments in Earth Surface Processes
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pituitary targeted pharmacotherapy for Cushing's disease is challenging and ineffective. Unlike octreotide and lanreotide, the multisomatostatin receptor (SST) analog pasireotide that exhibits SST5 greater than SST2 binding affinity offers potential for treating Cushing's disease. Because corticotroph cells express SST5 more abundantly than SST2, pasireotide likely exerts superior corticotroph action mainly through SST5. However, there is no direct evidence for this assumption, and moreover, the ligand effect on corticotroph SST2 is not known. We used AtT20 mouse pituitary corticotroph tumor cells stably overexpressing SST2 or SST5 and TtT/GF mouse pituitary folliculostellate cells stably or transiently expressing SST receptors to examine ligand-receptor activation by SST2- and SST5-selective agonists. We show that pasireotide was more potent than either octreotide or somatostatin-14 in mouse corticotroph cells. Pasireotide potency is not affected by SST2 abundance, SST2 antagonist treatment, or octreotide cotreatment in SST2-overexpressing cells. Pasireotide also does not induce SST2 internalization and attenuates octreotide or SRIF14-induced SST2 internalization only at superphysiological dose ranges. In contrast, octreotide attenuates pasireotide potency in SST5-overexpressing cells. Moreover, short exposure to pasireotide causes prolonged inhibition of forskolin or CRH-induced cAMP accumulation, in contrast to somatostatin-14- and SST2-selective agonists that induced postwithdrawal cAMP rebound. Long-term pasireotide signaling effects are enhanced by SST5 overexpression. The results indicate that SST5 determines short- and long-term enhanced pasireotide action in corticotroph cells, whereas the ligand action on SST2 is negligible.
    No preview · Article · Oct 2009 · The Journal of Clinical Endocrinology and Metabolism
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Acromegaly is a chronic disease with signs and symptoms due to growth hormone (GH) excess. The most frequent cause of acromegaly is a GH-producing pituitary adenoma. Chronic GH excess is accompanied by long-term complications of the locomotor (arthrosis) and cardiovascular (atherosclerosis, cardiomyopathy) systems and is, when untreated, associated with an increased mortality. The aim of treatment of acromegaly is to improve symptoms, to achieve local tumour mass control, and to decrease morbidity and mortality. Treatment options include surgery, medical therapy and radiotherapy. Transsphenoidal surgery is the first choice of treatment when a definitive cure can be achieved, particularly in the case of microadenomas and when decompression of surrounding structures (optic chiasm, ophthalmic motor nerves) is indicated. Primary medical therapy has been increasingly applied in recent years, especially when a priori chances of surgical cure are low (because of adenoma size and localization) and in patients with advanced age and/or serious co-morbidity. In addition, preoperative primary medical therapy may result in tumour shrinkage, facilitating tumour resection, and may reduce perioperative complications due to GH excess. Within the spectrum of medical therapy, long-acting somatostatin analogues (somatostatins) are considered as first-line treatment. Treatment with somatostatin analogues results in GH control in approximately 60% of patients. In addition, somatostatin analogues induce tumour shrinkage in 30–50% of patients, particularly when applied as primary therapy. Prolonged treatment with somatostatin analogues appears to be safe and is usually well tolerated. The currently available somatostatin analogues, octreotide and lanreotide, seem to be equally effective; however, this should still be evaluated in prospective, randomized trials evaluating efficacy with respect to GH control and tumour shrinkage. In patients with an insufficient clinical and biochemical response to somatostatin analogues, combination therapy with dopamine receptor agonists or the GH receptor antagonist pegvisomant usually leads to disease control. New developments in the medical therapy of acromegaly include the universal somatostatin receptor agonist pasireotide, which has a broader affinity for all somatostatin receptor (sst) subtypes compared with the currently available somatostatin analogues with preferential affinity for the sst2 receptor, and chimeric compounds that interact with both somatostatin and dopamine receptors with synergizing effects on GH secretion.
    Full-text · Article · Nov 2009 · Drugs
Show more